Eliot Forster

Eliot Forster has over 30 years’ experience in the biotech and pharmaceutical sectors. He was Chief Executive Officer of F-star Therapeutics (NASDAQ:FSTX) until its acquisition by inovX Pharma limited in March 2023, and formerly Chief Executive Officer of Immunocore (NASDAQ:IMCR), Chief Executive Officer of Creabilis, and President and Chief Executive Officer of Solace Pharmaceuticals. Earlier in his career, he held positions at Pfizer and GSK. Eliot currently serves as the Non-Executive Chairman of Avacta Group (AIM:AVCT), as the Non-Executive Chairman of Protalix Biotherapeutics (AMEX:PLX), as a Non-Executive Director of Immatics NV (NASDAQ:IMTX) and as the Chairman of Ochre Bio and Tessellate Bio, private biotechnology companies. He is an honorary visiting Professor at the Universities of Pavia Italy and Liverpool, UK.